Available Courses
Individualising Antithrombotic Strategies for Established CAD
- 1.00
Published:
Learning objectives
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
Changing Paradigms in Therapy to Unmet Needs
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
Overcoming the Challenges in Optimising GDMT in HF
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
TAVI Head-To-Head: Design, Data and Directions for Clinical Practice
- 1.00
Published:
Learning objectives
- Recall TAVI SMART trial data and the implications on clinical practice
- Describe novel valve designs and the impact on long-term performance
- Develop an expert-led approach to improving equitable access to TAVI
TAVI – Is Lifetime Patient Management the Alpha to Omega of Contemporary Practice?
- 1.00
Published:
Learning objectives
- Evaluate the factors influencing coronary access in different valve designs
- Formulate strategies to optimise coronary access based on valve characteristics
- Evaluate the role of valve design in reducing pacemaker implantation rates and enhancing future coronary access
- Learn the step-by-step process for achieving optimum implant depth during TAVI
- Apply guidelines and best practices for achieving and confirming optimum implant depth in TAVI procedures
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
Most Recent
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM